论文部分内容阅读
目的:探讨缬沙坦与前列地尔对早期糖尿病肾病患者尿微量蛋白的影响。方法:选取郑州市第二人民医院2015年1月至2016年8月收治的71例早期糖尿病肾病患者作为研究对象,根据入院顺序进行编号并利用随机数表法分为对照组35例和观察组36例,对照组患者予以前列地尔治疗,观察组患者实施缬沙坦与前列地尔治疗,对比两组患者的治疗效果。结果:两组治疗前尿素氮(BUN)、血肌酐(Cr)、24 h尿微量白蛋白各项指标比较,差异均无统计学意义(P>0.05),治疗后观察组24 h尿微量白蛋白水平明显低于对照组,差异具有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:缬沙坦与前列地尔治疗能够有效实现对早期糖尿病肾病患者尿微量蛋白的控制,且安全性高。
Objective: To investigate the effects of valsartan and alprostadil on urinary microalbuminuria in patients with early diabetic nephropathy. Methods: A total of 71 patients with early diabetic nephropathy admitted from January 2015 to August 2016 in Zhengzhou Second People’s Hospital were enrolled. According to the sequence of admission, patients were divided into control group (n = 35) and observation group Thirty-six patients in the control group were treated with alprostadil. Patients in the observation group were treated with valsartan and alprostadil, and the therapeutic effect was compared between the two groups. Results: There was no significant difference between the two groups in the indexes of BUN, Cr and 24 h urine microalbuminuria before treatment (P> 0.05) The protein level was significantly lower than the control group, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Valsartan and alprostadil can effectively control urinary microalbuminuria in patients with early diabetic nephropathy, and its safety is high.